Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Atezolizumab for Subsequent Line Treatment for Small Cell Lung Cancer
NCT04919382Phase 2Recruiting
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and temozolomide in small cell lung cancer (SCLC) (2 cohorts). Primary endpoint: Objective Response Rate up to 2 years. Started Jan 2022; status: recruiting.
02
Drugs
atezolizumabtemozolomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04919382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919382.